Skip to content
The Policy VaultThe Policy Vault

Cosentyx subcutaneous — Medica

Psoriatic Arthritis

Initial criteria

  • Patient meets the standard Inflammatory Conditions – Cosentyx Subcutaneous Prior Authorization Policy criteria
  • Patient is ≥ 18 years of age AND has tried TWO of Enbrel, an adalimumab product, Otezla, Rinvoq/Rinvoq LQ, Skyrizi subcutaneous, an ustekinumab subcutaneous product, Taltz, Tremfya subcutaneous, and Xeljanz/XR; OR
  • Patient is < 18 years of age AND has tried ONE of Enbrel, Otezla, Rinvoq/LQ, or an ustekinumab subcutaneous product

Approval duration

6 months